SillaJen Presents SJ-600 Research Results Poster at AACR

Shinilgen announced on the 8th that the research team led by Professor Lee Dong-seop of Seoul National University College of Medicine presented the research results of its anticancer virus platform SJ-600 series in a poster session at the American Association for Cancer Research Annual Meeting (AACR 2024). AACR, held in San Diego, California, USA, from the 5th to the 10th (local time), is considered one of the world's top three cancer conferences along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).

[Photo by Shillajen]

The research team disclosed a total of two research results this time. The first study evaluated the anticancer efficacy of repeated intravenous administration of the SJ-600 series in an immune-competent breast cancer mouse model with neutralizing antibodies formed against the vaccinia virus and analyzed immunological changes within tumor tissues. While conventional anticancer viruses lost their efficacy in mice with neutralizing antibodies, the SJ-600 series showed consistent anticancer efficacy even in mice with neutralizing antibodies. It was also confirmed that an antitumor immune environment was induced by increased infiltration and activation of cytotoxic T cells within the tumor tissue. The company stated, "This study is the first to prove that the efficacy of an anticancer virus is maintained in mice with sufficient neutralizing antibodies," and explained, "The SJ-600 series technology demonstrates that repeated intravenous administration can achieve complete tumor remission."

The other study evaluated whether the SJ-600 series, through intravenous injection, effectively delivers anticancer effects not only to primary tumors but also to metastatic cancers. The research team demonstrated tumor growth suppression through repeated intravenous administration of the SJ-600 series in a liver metastasis colorectal cancer model. They observed that the SJ-600 series anticancer virus induced widespread cell death in all metastatic tumor tissues starting the day after intravenous administration. The company described this as "a highly encouraging result proving the efficacy of repeated intravenous administration of the SJ-600 series even in metastatic models, which are not typical superficial solid tumors."

A Shinilgen official said, "These research results are very meaningful as they prove that strong anticancer effects can be achieved via intravenous administration even in metastatic cancer without being affected by neutralizing antibodies," and added, "Shinilgen and the Seoul National University College of Medicine research team will continue to verify the efficacy of the SJ-600 series through ongoing collaboration."